Coya Therapeutics, Inc. 8-K Filing
Ticker: COYA · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $4.2 million |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Coya Therapeutics, Inc. (ticker: COYA) to the SEC on Dec 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar); $4.2 million (eutics, Inc. (the "Company") received a $4.2 million milestone payment under the Development).
How long is this filing?
Coya Therapeutics, Inc.'s 8-K filing is 1 pages with approximately 434 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-12-17 08:00:15
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
- $4.2 million — eutics, Inc. (the "Company") received a $4.2 million milestone payment under the Development
Filing Documents
- d729078d8k.htm (8-K) — 22KB
- 0001193125-25-321737.txt ( ) — 136KB
- coya-20251216.xsd (EX-101.SCH) — 3KB
- coya-20251216_lab.xml (EX-101.LAB) — 18KB
- coya-20251216_pre.xml (EX-101.PRE) — 11KB
- d729078d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COYA THERAPEUTICS, INC. Date: December 17, 2025 By: /s/ Arun Swaminathan Ph.D. Arun Swaminathan Ph.D. Chief Executive Officer